Enanta Pharmaceuticals Inc
NASDAQ:ENTA
Enanta Pharmaceuticals Inc
Research & Development
Enanta Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Enanta Pharmaceuticals Inc
NASDAQ:ENTA
|
Research & Development
-$99.9m
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-14%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Enanta Pharmaceuticals Inc
Glance View
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The firm has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The firm has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The firm's subsidiary is Enanta Pharmaceuticals Security Corporation.
See Also
What is Enanta Pharmaceuticals Inc's Research & Development?
Research & Development
-99.9m
USD
Based on the financial report for Dec 31, 2025, Enanta Pharmaceuticals Inc's Research & Development amounts to -99.9m USD.
What is Enanta Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-14%
Over the last year, the Research & Development growth was 19%. The average annual Research & Development growth rates for Enanta Pharmaceuticals Inc have been 14% over the past three years , 7% over the past five years , and -14% over the past ten years .
